A cannabis supply agreement with a Canadian Licensed Producer is not a standard commodity contract. The regulatory obligations on both sides, the compliance interdependencies, and the batch-level documentation requirements make it a specialised instrument that most procurement teams encounter for the first time. Getting the terms wrong delays shipments, triggers customs holds, and puts import licences at risk.
This guide covers the five contract elements most commonly overlooked, and the compliance questions to raise with any Canadian LP before the first signature.
Why cannabis supply agreements carry unique regulatory weight
A cannabis supply agreement with a Canadian Health Canada Licensed Producer is not a standard commodity contract. The regulatory obligations on both sides, the compliance interdependencies, and the batch-level documentation requirements make it a specialised instrument that most procurement teams encounter for the first time. Getting the terms wrong delays shipments, triggers customs holds, and puts import licences at risk.
Every shipment of medical-grade cannabis between a Canadian LP and a foreign importer requires an export permit issued under the Cannabis Act, and a corresponding import permit issued by the destination country's authority. Neither party can waive that requirement by contract.
Standard force majeure, delivery, and penalty clauses assume a commercial shipment that moves on the buyer's instruction. Cannabis shipments do not. A missing import permit number, an expired export authorisation, or a COA panel that does not match the destination country's testing standard can hold a shipment at the border regardless of what the contract says about delivery timelines. Five clauses address the most common points of failure.
The 5-clause cannabis supply agreement checklist for B2B buyers
Five clauses consistently cause problems for procurement teams sourcing from Canadian LPs. Each one reflects a regulatory reality that standard commercial contracts were not designed to handle.
1. Permit-contingent delivery obligations
Standard commercial contracts treat the seller's failure to deliver on time as a breach. In cannabis trade, delivery depends on permits that neither party controls entirely. A well-structured supply agreement suspends delivery obligations for both parties while a required export or import permit is pending, without treating the delay as a breach. It also specifies which party is responsible for initiating each permit application and within what lead time relative to the planned shipment date.
The International Narcotics Control Board (INCB) requires that export permits reference the corresponding import permit issued by the destination country. Confirm the agreement assigns responsibility for providing that import permit number to the buyer, in writing, at least 10 business days before shipment.
2. COA specification and testing standard alignment
Certificates of analysis from a Canadian LP will typically reflect ISO/IEC 17025-accredited testing. The destination country may impose additional panel requirements or different acceptable thresholds. Germany's medical channel expects testing panels aligned with EU-GMP expectations. Australia's TGO 93 standard specifies its own residue and contaminant limits.
Name the specific testing standard the COA must conform to in the contract itself, not just confirm the LP holds ISO/IEC 17025 accreditation. Accreditation is a capability signal. Panel scope and thresholds belong in product specifications appended as a schedule.
3. Batch substitution and strain consistency terms
Batch substitution is a common source of disputes. An LP unable to supply the contracted cultivar may offer a substitute batch of equivalent potency. From a compliance standpoint, the substitute batch carries a different COA, different strain data, and may require a new import permit if the destination country's permit specifies the contracted cultivar. Define in the agreement whether substitution is permitted, under what conditions, with what notice, and whether it requires approval before shipment.
For pharmaceutical distribution, this clause should explicitly prohibit unconsented substitution.
4. Documentation delivery timeline and failure consequences
A cannabis shipment requires a package of documents that typically includes the export permit, COA, phytosanitary certificate, certificate of origin, and any country-specific import documentation. A missing document can hold a shipment in customs indefinitely. Specify in the agreement which documents the LP is responsible for delivering, the deadline relative to the shipment date, and the consequence (price reduction or shipment postponement) if documents arrive late.
This is not about penalising the LP for regulatory delays outside their control. It is about creating a clear accountability structure so both parties know who is responsible for what, and by when. For context on the full documentation chain, see our guide to how Canadian LPs obtain Health Canada export permits.
5. Quality dispute resolution and rejection protocol
If a buyer receives a batch that does not conform to contracted specifications, the rejection protocol matters enormously. Cannabis cannot simply be returned across an international border. Most destination countries prohibit re-export of imported cannabis. A well-structured supply agreement addresses this by specifying: the notification window for raising a quality dispute, the testing authority whose results are binding, the LP's remediation obligations (replacement batch, credit, or price reduction), and the disposal protocol for non-conforming product in the destination market.
Leaving this clause vague often means the only practical remedy is credit against future orders. That is inadequate in a single-supplier arrangement. For COA interpretation, see our B2B COA guide.
Due diligence questions to ask any Canadian LP before signing
A supply agreement is only as reliable as the LP behind it. A contract can be well-drafted and still deliver poor outcomes if the LP's compliance infrastructure does not match the destination market. Pre-contract due diligence should cover at least these six areas.
| Area | Question to ask | What a strong answer looks like |
|---|---|---|
| Export authorisation | Does your Health Canada licence include export authorisation under the Cannabis Act? | LP can produce the authorisation on request, not just confirm it verbally |
| COA testing | Which ISO/IEC 17025-accredited laboratory conducts your batch testing? | Named third-party lab with verifiable accreditation scope |
| GMP alignment | What GMP framework governs your facility? Have you hosted international buyer audits? | Health Canada GMP with EU-GMP-aligned SOPs; previous audit experience in target market |
| Batch consistency | What is your batch-to-batch potency variance on your primary export cultivars? | Variance within plus or minus 2% THC across three consecutive batches, supported by COAs |
| Documentation lead time | How far in advance of shipment can you confirm all required export documentation? | 10 business days minimum; LP has a documented export documentation SOP |
| Batch size | What is your minimum and maximum export batch size, and what is your current inventory lead time? | Clear minimums; ability to provide 30-day pipeline visibility |
LPs who answer these questions with documentation rather than assurances are operating at the level that regulated medical markets require. For a broader framework on LP evaluation, see our guide to vetting a Canadian LP.
How supply agreement structure differs by destination market
All five clauses apply across B2B cannabis trade. How they are drafted varies by destination, because the regulatory frameworks differ significantly.
Germany
German medical cannabis importers operate under the oversight of the Bundesopiumstelle (Federal Opium Agency). Import permits are issued per shipment and specify the approved cultivar, quantity, and LP. Supply agreements for the German market need to address how the buyer will obtain updated import permits for each shipment, and how the parties will handle processing delays without triggering delivery penalties.
EU-GMP alignment is an expectation, not a preference, in the German medical channel. Confirm the LP's quality system documentation is structured for EU-GMP review before contracting. Our guide to EU-GMP versus Health Canada GMP explains what that alignment entails in practice.
Australia
Australian importers work under a dual-authority framework: the Therapeutic Goods Administration (TGA) for medicinal cannabis product approvals, and the Office of Drug Control (ODC) for import licence administration. Supply agreements for the Australian market must reference TGO 93 compliance as the applicable testing standard and should define which party is responsible for obtaining TGA product approval if the cultivar is not yet on the Australian Register of Therapeutic Goods.
Israel
The Israel Medical Cannabis Agency (IMCA) governs import permits and sets standards under IMC-GAP and IMC-GMP frameworks. Israeli pharmaceutical distributors expect batch-level traceability records aligned with IMC-GMP, which has its own documentation requirements distinct from EU-GMP. Confirm the LP's traceability system can produce IMCA-compliant records before contracting, and factor the buyer's import permit application timeline into the lead time provisions.
AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower. We hold export authorisation under the Cannabis Act and maintain ISO/IEC 17025-tested batch records, full traceability documentation, and EU-GMP-aligned quality system SOPs. International buyers sourcing for the German medical channel, Australian pharmaceutical supply, or Israeli pharmaceutical distribution will find our export documentation infrastructure is built to support the due diligence process described above, from pre-contract audits through to per-shipment COA delivery.
Frequently Asked Questions
What is a cannabis supply agreement?
A cannabis supply agreement is a commercial contract between a Licensed Producer and a B2B buyer (typically an international importer, pharmaceutical distributor, or regulated wholesale buyer) that governs the terms of repeated cannabis product supply. Unlike a standard commodity contract, it must account for permit-dependent shipment timelines, COA specification requirements, and the regulatory frameworks of both the exporting and importing country.
Does a Canadian LP need special authorisation to export cannabis?
Yes. Under the Cannabis Act, a Canadian LP must hold export authorisation as part of its Health Canada licence, and must obtain a per-shipment export permit from Health Canada. The export permit references the importer's import permit from the destination country. Both must be in place before a shipment can legally cross the Canadian border.
What testing standards should a cannabis COA meet for European markets?
For the German and broader EU medical market, COAs should reflect testing by an ISO/IEC 17025-accredited laboratory, with panel scope and thresholds aligned to EU-GMP quality expectations. Specify the required panel scope in the product specifications appended to the supply agreement. Do not assume the LP's standard COA will satisfy destination country requirements.
What happens if a cannabis batch is rejected at customs?
Rejected cannabis batches face a narrow set of outcomes, since most importing countries prohibit re-export. Ensure the supply agreement specifies the notification window for quality disputes, the testing authority whose findings are binding, and the LP's remediation obligations (batch replacement, credit, or disposal cost coverage).
How long does it typically take to finalise a cannabis supply agreement with a Canadian LP?
From initial due diligence to a signed supply agreement, the process typically runs 6 to 12 weeks for buyers new to the Canadian market. The main variables are the LP's experience with international contracts, the buyer's internal legal review timeline, and how quickly the destination country's import permit process can be initiated. Working with an LP that has a documented export documentation SOP shortens this materially.
What is the minimum batch size for cannabis exports from Canada?
Minimum batch sizes vary by LP. Most Canadian LPs operate indoor facilities with batch production cycles of 8 to 12 weeks. Minimum commercial export batches typically start at 5 kg of dried flower. Confirm minimum order quantities, inventory lead times, and whether the LP can provide 30-day forward pipeline visibility during negotiation.
